The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome

The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome

Avoidance of apoptosis is a key mechanism that malignancies, including acute leukemias and MDS, utilize in order to proliferate and resist chemotherapy. Recently, venetoclax, an inhibitor of the anti-apoptotic protein BCL-2, has been approved for the treatment of upfront AML in an unfit, elderly pop...

Full description

Bibliographic Details
Main Authors: Amanda McBride, Sarah Houtmann, Lindsay Wilde, Carlos Vigil, Christine M. Eischen, Margaret Kasner, Neil Palmisiano
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-03-01
Series:Frontiers in Oncology
Subjects:
BCL-2
venetoclax
AML
ALL
MDS
intrinsic apoptosis
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00192/full
id doaj-e8b5e989cb64442eaae3a69b4db82eca
record_format Article
spelling doaj-e8b5e989cb64442eaae3a69b4db82eca2020-11-25T03:35:57ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2019-03-01910.3389/fonc.2019.00192442772The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic SyndromeAmanda McBride0Sarah Houtmann1Lindsay Wilde2Carlos Vigil3Christine M. Eischen4Margaret Kasner5Neil Palmisiano6Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United StatesDepartment of Medicine, Thomas Jefferson University, Philadelphia, PA, United StatesDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United StatesDivision of Hematology, Oncology and Blood and Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, IA, United StatesDepartment of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United StatesDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United StatesDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United StatesAvoidance of apoptosis is a key mechanism that malignancies, including acute leukemias and MDS, utilize in order to proliferate and resist chemotherapy. Recently, venetoclax, an inhibitor of the anti-apoptotic protein BCL-2, has been approved for the treatment of upfront AML in an unfit, elderly population. This paper reviews the pre-clinical and clinical data for apoptosis inhibitors currently in development for the treatment of AML, ALL, and MDS.https://www.frontiersin.org/article/10.3389/fonc.2019.00192/fullBCL-2venetoclaxAMLALLMDSintrinsic apoptosis
collection DOAJ
language English
format Article
sources DOAJ
author Amanda McBride
Sarah Houtmann
Lindsay Wilde
Carlos Vigil
Christine M. Eischen
Margaret Kasner
Neil Palmisiano
spellingShingle Amanda McBride
Sarah Houtmann
Lindsay Wilde
Carlos Vigil
Christine M. Eischen
Margaret Kasner
Neil Palmisiano
The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome
Frontiers in Oncology
BCL-2
venetoclax
AML
ALL
MDS
intrinsic apoptosis
author_facet Amanda McBride
Sarah Houtmann
Lindsay Wilde
Carlos Vigil
Christine M. Eischen
Margaret Kasner
Neil Palmisiano
author_sort Amanda McBride
title The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome
title_short The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome
title_full The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome
title_fullStr The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome
title_full_unstemmed The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome
title_sort role of inhibition of apoptosis in acute leukemias and myelodysplastic syndrome
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2019-03-01
description Avoidance of apoptosis is a key mechanism that malignancies, including acute leukemias and MDS, utilize in order to proliferate and resist chemotherapy. Recently, venetoclax, an inhibitor of the anti-apoptotic protein BCL-2, has been approved for the treatment of upfront AML in an unfit, elderly population. This paper reviews the pre-clinical and clinical data for apoptosis inhibitors currently in development for the treatment of AML, ALL, and MDS.
topic BCL-2
venetoclax
AML
ALL
MDS
intrinsic apoptosis
url https://www.frontiersin.org/article/10.3389/fonc.2019.00192/full
work_keys_str_mv AT amandamcbride theroleofinhibitionofapoptosisinacuteleukemiasandmyelodysplasticsyndrome
AT sarahhoutmann theroleofinhibitionofapoptosisinacuteleukemiasandmyelodysplasticsyndrome
AT lindsaywilde theroleofinhibitionofapoptosisinacuteleukemiasandmyelodysplasticsyndrome
AT carlosvigil theroleofinhibitionofapoptosisinacuteleukemiasandmyelodysplasticsyndrome
AT christinemeischen theroleofinhibitionofapoptosisinacuteleukemiasandmyelodysplasticsyndrome
AT margaretkasner theroleofinhibitionofapoptosisinacuteleukemiasandmyelodysplasticsyndrome
AT neilpalmisiano theroleofinhibitionofapoptosisinacuteleukemiasandmyelodysplasticsyndrome
AT amandamcbride roleofinhibitionofapoptosisinacuteleukemiasandmyelodysplasticsyndrome
AT sarahhoutmann roleofinhibitionofapoptosisinacuteleukemiasandmyelodysplasticsyndrome
AT lindsaywilde roleofinhibitionofapoptosisinacuteleukemiasandmyelodysplasticsyndrome
AT carlosvigil roleofinhibitionofapoptosisinacuteleukemiasandmyelodysplasticsyndrome
AT christinemeischen roleofinhibitionofapoptosisinacuteleukemiasandmyelodysplasticsyndrome
AT margaretkasner roleofinhibitionofapoptosisinacuteleukemiasandmyelodysplasticsyndrome
AT neilpalmisiano roleofinhibitionofapoptosisinacuteleukemiasandmyelodysplasticsyndrome
_version_ 1724552261919571968

Similar Items